Clinical Trial Update: Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for HBI-8000 in combination with nivolumab across melanoma, renal cell carcinoma, and non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• HBI-8000
• nivolumab (nivolumab)

Snippet

Sponsor: HUYABIO International, LLC. | Conditions: Melanoma, Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED